Details of the Drug

General Information of Drug (ID: DMQTJSX)

Drug Name
Fluvoxamine
Synonyms
Dumyrox; Fluvoxamina; Fluvoxaminum; Fluvoxamina [INN-Spanish]; Fluvoxamine (INN); Fluvoxamine [INN:BAN]; Fluvoxamine-CR; Fluvoxaminum [INN-Latin]; Luvox (TN); (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime; 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; 2-[({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene}amino)oxy]ethanamine
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1]
Obsessive compulsive disorder 6B20 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [3]
Therapeutic Class
Antidepressants
Affected Organisms
Humans and other mammals
ATC Code
N06AB08: Fluvoxamine
N06AB: Selective serotonin reuptake inhibitors
N06A: ANTIDEPRESSANTS
N06: PSYCHOANALEPTICS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 318.33
Logarithm of the Partition Coefficient (xlogp) 2.6
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
Chemical Identifiers
Formula
C15H21F3N2O2
IUPAC Name
2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
Canonical SMILES
COCCCC/C(=N\\OCCN)/C1=CC=C(C=C1)C(F)(F)F
InChI
InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+
InChIKey
CJOFXWAVKWHTFT-XSFVSMFZSA-N
Cross-matching ID
PubChem CID
5324346
ChEBI ID
CHEBI:5138
CAS Number
54739-18-3
UNII
O4L1XPO44W
DrugBank ID
DB00176
TTD ID
D03HFG
VARIDT ID
DR00390
ACDINA ID
D00290
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Regulation of Drug Effects [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serotonin transporter (SERT) DTT SLC6A4 8.76E-01 7.18E-05 6.19E-04
P-glycoprotein 1 (ABCB1) DTP P-GP 6.54E-01 1.95E-01 4.04E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fluvoxamine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Aprepitant DM053KT Moderate Decreased metabolism of Fluvoxamine caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [7]
Sertraline DM0FB1J Moderate Decreased metabolism of Fluvoxamine caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [8]
Trimipramine DM1SC8M Major Decreased metabolism of Fluvoxamine caused by Trimipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [9]
Cyclobenzaprine DM1YBRM Major Additive serotonergic effects by the combination of Fluvoxamine and Cyclobenzaprine. Depression [6A70-6A7Z] [10]
Imipramine DM2NUH3 Major Decreased metabolism of Fluvoxamine caused by Imipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [9]
Nortriptyline DM4KDYJ Major Additive serotonergic effects by the combination of Fluvoxamine and Nortriptyline. Depression [6A70-6A7Z] [9]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Fluvoxamine and Vilazodone. Depression [6A70-6A7Z] [10]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Fluvoxamine and Nefazodone. Depression [6A70-6A7Z] [10]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Fluvoxamine and Selegiline. Depression [6A70-6A7Z] [11]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Fluvoxamine and Vortioxetine. Depression [6A70-6A7Z] [10]
Duloxetine DM9BI7M Major Decreased metabolism of Fluvoxamine caused by Duloxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [12]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Fluvoxamine and Isocarboxazid. Depression [6A70-6A7Z] [11]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Fluvoxamine and Milnacipran. Depression [6A70-6A7Z] [10]
Escitalopram DMFK9HG Moderate Decreased metabolism of Fluvoxamine caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [13]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Fluvoxamine and Tranylcypromine. Depression [6A70-6A7Z] [11]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Fluvoxamine and Desvenlafaxine. Depression [6A70-6A7Z] [10]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Fluvoxamine and Phenelzine. Depression [6A70-6A7Z] [11]
Clomipramine DMINRKW Major Additive serotonergic effects by the combination of Fluvoxamine and Clomipramine. Depression [6A70-6A7Z] [9]
Trazodone DMK1GBJ Major Additive serotonergic effects by the combination of Fluvoxamine and Trazodone. Depression [6A70-6A7Z] [10]
Amitriptyline DMK7F9S Major Decreased metabolism of Fluvoxamine caused by Amitriptyline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [9]
Amoxapine DMKITQE Major Additive serotonergic effects by the combination of Fluvoxamine and Amoxapine. Depression [6A70-6A7Z] [9]
Mirtazapine DML53ZJ Major Additive serotonergic effects by the combination of Fluvoxamine and Mirtazapine. Depression [6A70-6A7Z] [14]
Protriptyline DMNHTZI Major Decreased metabolism of Fluvoxamine caused by Protriptyline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [9]
Doxepin DMPI98T Major Additive serotonergic effects by the combination of Fluvoxamine and Doxepin. Depression [6A70-6A7Z] [9]
Maprotiline DMPWB7T Major Additive serotonergic effects by the combination of Fluvoxamine and Maprotiline. Depression [6A70-6A7Z] [10]
Venlafaxine DMR6QH0 Major Additive serotonergic effects by the combination of Fluvoxamine and Venlafaxine. Depression [6A70-6A7Z] [10]
⏷ Show the Full List of 26 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Fluvoxamine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Fluvoxamine and Methylene blue. Acquired methaemoglobinaemia [3A93] [15]
Glimepiride DM5FSJA Moderate Decreased metabolism of Fluvoxamine caused by Glimepiride mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [16]
Repaglinide DM5SXUV Moderate Decreased metabolism of Fluvoxamine caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [17]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Fluvoxamine and Glibenclamide. Acute diabete complication [5A2Y] [18]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Fluvoxamine and Tolazamide. Acute diabete complication [5A2Y] [18]
Pioglitazone DMKJ485 Moderate Decreased metabolism of Fluvoxamine caused by Pioglitazone mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [8]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Fluvoxamine and Insulin-glulisine. Acute diabete complication [5A2Y] [18]
Acetohexamide DMR6N7H Moderate Increased risk of hypoglycemia by the combination of Fluvoxamine and Acetohexamide. Acute diabete complication [5A2Y] [18]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Fluvoxamine and Insulin-aspart. Acute diabete complication [5A2Y] [19]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Fluvoxamine and Glipizide. Acute diabete complication [5A2Y] [18]
Midostaurin DMI6E0R Moderate Decreased metabolism of Fluvoxamine caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [20]
Oliceridine DM6MDCF Major Decreased metabolism of Fluvoxamine caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [21]
Terfenadine DM4KLPT Major Decreased metabolism of Fluvoxamine caused by Terfenadine mediated inhibition of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [22]
Loratadine DMF3AN7 Moderate Decreased metabolism of Fluvoxamine caused by Loratadine mediated inhibition of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [8]
Tacrine DM51FY6 Moderate Decreased metabolism of Fluvoxamine caused by Tacrine mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [23]
Galantamine DMEO794 Moderate Decreased metabolism of Fluvoxamine caused by Galantamine mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [24]
Donepezil DMIYG7Z Minor Decreased metabolism of Fluvoxamine caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [25]
Inotersen DMJ93CT Moderate Increased risk of bleeding by the combination of Fluvoxamine and Inotersen. Amyloidosis [5D00] [26]
Ranolazine DM0C9IL Major Decreased metabolism of Fluvoxamine caused by Ranolazine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [27]
Ivabradine DM0L594 Moderate Decreased metabolism of Fluvoxamine caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [28]
Bepridil DM0RKS4 Moderate Decreased metabolism of Fluvoxamine caused by Bepridil mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [8]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Fluvoxamine caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [29]
Nifedipine DMSVOZT Moderate Decreased metabolism of Fluvoxamine caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [8]
Buspirone DMBS632 Major Additive serotonergic effects by the combination of Fluvoxamine and Buspirone. Anxiety disorder [6B00-6B0Z] [10]
Clorazepate DMC3JST Moderate Decreased metabolism of Fluvoxamine caused by Clorazepate mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [8]
Alprazolam DMC7XDN Moderate Decreased metabolism of Fluvoxamine caused by Alprazolam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [30]
Methylphenobarbital DMDSWAG Moderate Antagonize the effect of Fluvoxamine when combined with Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [31]
Halazepam DMPFWO6 Moderate Decreased metabolism of Fluvoxamine caused by Halazepam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [30]
Clobazam - Lundbeck DMW1OQ0 Moderate Decreased metabolism of Fluvoxamine caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [32]
Cilostazol DMZMSCT Major Decreased metabolism of Fluvoxamine caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [28]
Budesonide DMJIBAW Moderate Decreased metabolism of Fluvoxamine caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [33]
Aminophylline DML2NIB Major Decreased metabolism of Fluvoxamine caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [34]
Roflumilast DMPGHY8 Moderate Decreased metabolism of Fluvoxamine caused by Roflumilast mediated inhibition of CYP450 enzyme. Asthma [CA23] [28]
Zileuton DMVRIC2 Moderate Decreased metabolism of Fluvoxamine caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [8]
Pimecrolimus DMZLGRB Minor Decreased metabolism of Fluvoxamine caused by Pimecrolimus mediated inhibition of CYP450 enzyme. Atopic eczema [EA80] [35]
Methylphenidate DM7SJD6 Moderate Decreased metabolism of Fluvoxamine caused by Methylphenidate. Attention deficit hyperactivity disorder [6A05] [36]
Desipramine DMT2FDC Major Decreased metabolism of Fluvoxamine caused by Desipramine mediated inhibition of CYP450 enzyme. Attention deficit hyperactivity disorder [6A05] [9]
Erythromycin DM4K7GQ Moderate Decreased metabolism of Fluvoxamine caused by Erythromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [8]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Fluvoxamine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [8]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Fluvoxamine and Linezolid. Bacterial infection [1A00-1C4Z] [37]
Rabeprazole DMMZXIW Moderate Decreased metabolism of Fluvoxamine caused by Rabeprazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [38]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Fluvoxamine caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [8]
Retigabine DMGNYIH Moderate Antagonize the effect of Fluvoxamine when combined with Retigabine. Behcet disease [4A62] [31]
Lamotrigine DM8SXYG Moderate Antagonize the effect of Fluvoxamine when combined with Lamotrigine. Bipolar disorder [6A60] [31]
Cariprazine DMJYDVK Moderate Decreased metabolism of Fluvoxamine caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [39]
Pexidartinib DMS2J0Z Major Decreased metabolism of Fluvoxamine caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [40]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Fluvoxamine caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [41]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Fluvoxamine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [42]
HKI-272 DM6QOVN Major Decreased metabolism of Fluvoxamine caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [43]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Fluvoxamine caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [8]
Palbociclib DMD7L94 Moderate Decreased metabolism of Fluvoxamine caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [28]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Fluvoxamine caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [8]
Tamoxifen DMLB0EZ Moderate Decreased metabolism of Fluvoxamine caused by Tamoxifen mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [8]
Toremifene DMQYUWG Moderate Decreased metabolism of Fluvoxamine caused by Toremifene mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
Bosutinib DMTI8YE Moderate Decreased metabolism of Fluvoxamine caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [28]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Fluvoxamine and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [45]
Estradiol DMUNTE3 Moderate Decreased metabolism of Fluvoxamine caused by Estradiol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [8]
Mannitol DMSCDY9 Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Mannitol. Bronchiectasis [CA24] [46]
Dofetilide DMPN1TW Moderate Decreased metabolism of Fluvoxamine caused by Dofetilide mediated inhibition of CYP450 enzyme. Cardiac arrhythmia [BC9Z] [47]
Atorvastatin DMF28YC Moderate Decreased metabolism of Fluvoxamine caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [48]
Macitentan DMP79A1 Moderate Decreased metabolism of Fluvoxamine caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [49]
PF-04449913 DMSB068 Moderate Decreased metabolism of Fluvoxamine caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [50]
Pregabalin DMDVP3B Moderate Antagonize the effect of Fluvoxamine when combined with Pregabalin. Chronic obstructive pulmonary disease [CA22] [31]
Indacaterol DMQJHR7 Minor Decreased metabolism of Fluvoxamine caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [51]
Phenylbutazone DMAYL0T Moderate Increased risk of bleeding by the combination of Fluvoxamine and Phenylbutazone. Chronic pain [MG30] [26]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Fluvoxamine and Dihydrocodeine. Chronic pain [MG30] [52]
Ketoprofen DMRKXPT Moderate Increased risk of bleeding by the combination of Fluvoxamine and Ketoprofen. Chronic pain [MG30] [26]
Morphine DMRMS0L Moderate Additive CNS depression effects by the combination of Fluvoxamine and Morphine. Chronic pain [MG30] [52]
Levetiracetam DMTGDN8 Moderate Antagonize the effect of Fluvoxamine when combined with Levetiracetam. Chronic pain [MG30] [31]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Fluvoxamine and Levomilnacipran. Chronic pain [MG30] [10]
Anisindione DM2C48U Moderate Decreased metabolism of Fluvoxamine caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [53]
Regorafenib DMHSY1I Moderate Increased risk of bleeding by the combination of Fluvoxamine and Regorafenib. Colorectal cancer [2B91] [26]
Irinotecan DMP6SC2 Moderate Decreased metabolism of Fluvoxamine caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [13]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Fluvoxamine caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [8]
Desogestrel DM27U4Y Moderate Decreased metabolism of Fluvoxamine caused by Desogestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [8]
Ulipristal DMBNI20 Minor Decreased metabolism of Fluvoxamine caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [28]
Etonogestrel DMKA8J4 Moderate Decreased metabolism of Fluvoxamine caused by Etonogestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [8]
Levobupivacaine DM783CH Moderate Decreased metabolism of Fluvoxamine caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [28]
Lidocaine DML4ZOT Moderate Decreased metabolism of Fluvoxamine caused by Lidocaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [8]
Cocaine DMSOX7I Moderate Decreased metabolism of Fluvoxamine caused by Cocaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [8]
Ropivacaine DMSPJG2 Moderate Decreased metabolism of Fluvoxamine caused by Ropivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [54]
Alfentanil DMVO0UB Major Additive serotonergic effects by the combination of Fluvoxamine and Alfentanil. Corneal disease [9A76-9A78] [10]
Remifentanil DMZTXCH Major Additive serotonergic effects by the combination of Fluvoxamine and Remifentanil. Corneal disease [9A76-9A78] [10]
Ardeparin DMYRX8B Moderate Increased risk of bleeding by the combination of Fluvoxamine and Ardeparin. Coronary thrombosis [BA43] [26]
Nimodipine DMQ0RKZ Moderate Decreased metabolism of Fluvoxamine caused by Nimodipine mediated inhibition of CYP450 enzyme. Coronary vasospastic disease [BA85] [8]
Oxtriphylline DMLHSE3 Major Decreased metabolism of Fluvoxamine caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [34]
Methadone DMTW6IU Moderate Decreased metabolism of Fluvoxamine caused by Methadone mediated inhibition of CYP450 enzyme. Cough [MD12] [55]
Dextromethorphan DMUDJZM Major Additive serotonergic effects by the combination of Fluvoxamine and Dextromethorphan. Cough [MD12] [10]
Mifepristone DMGZQEF Moderate Decreased metabolism of Fluvoxamine caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [56]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Fluvoxamine caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [28]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Fluvoxamine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [57]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Fluvoxamine and Ethanol. Cystitis [GC00] [58]
Danaparoid DM6CLBN Moderate Increased risk of bleeding by the combination of Fluvoxamine and Danaparoid. Deep vein thrombosis [BD71] [26]
Rivaroxaban DMQMBZ1 Moderate Increased risk of bleeding by the combination of Fluvoxamine and Rivaroxaban. Deep vein thrombosis [BD71] [26]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Fluvoxamine caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [59]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Fluvoxamine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [60]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Fluvoxamine caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [8]
Citalopram derivative 1 DMITX1G Major Decreased metabolism of Fluvoxamine caused by Citalopram derivative 1 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [61]
PMID28870136-Compound-48 DMPIM9L Major Decreased metabolism of Fluvoxamine caused by PMID28870136-Compound-48 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [34]
PMID28870136-Compound-49 DMTUC9E Moderate Decreased metabolism of Fluvoxamine caused by PMID28870136-Compound-49 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [62]
Ospemifene DMC4GEI Moderate Decreased metabolism of Fluvoxamine caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [63]
Fenfluramine DM0762O Major Additive serotonergic effects by the combination of Fluvoxamine and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [10]
Diazepam DM08E9O Major Decreased metabolism of Fluvoxamine caused by Diazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [30]
Zonisamide DM0DTF7 Moderate Antagonize the effect of Fluvoxamine when combined with Zonisamide. Epilepsy/seizure [8A61-8A6Z] [31]
Felbamate DM1V5ZS Moderate Antagonize the effect of Fluvoxamine when combined with Felbamate. Epilepsy/seizure [8A61-8A6Z] [31]
Oxcarbazepine DM5PU6O Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Oxcarbazepine. Epilepsy/seizure [8A61-8A6Z] [31]
Mephenytoin DM5UGDK Moderate Decreased metabolism of Fluvoxamine caused by Mephenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [64]
Methsuximide DM6L5VO Moderate Antagonize the effect of Fluvoxamine when combined with Methsuximide. Epilepsy/seizure [8A61-8A6Z] [31]
Gabapentin DM6T924 Moderate Antagonize the effect of Fluvoxamine when combined with Gabapentin. Epilepsy/seizure [8A61-8A6Z] [31]
Valproate DMCFE9I Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Valproate. Epilepsy/seizure [8A61-8A6Z] [31]
Ethosuximide DMDZ9LT Moderate Antagonize the effect of Fluvoxamine when combined with Ethosuximide. Epilepsy/seizure [8A61-8A6Z] [31]
Tiagabine DMKSQG0 Moderate Antagonize the effect of Fluvoxamine when combined with Tiagabine. Epilepsy/seizure [8A61-8A6Z] [31]
Stiripentol DMMSDOY Moderate Decreased metabolism of Fluvoxamine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [28]
Phenytoin DMNOKBV Moderate Decreased metabolism of Fluvoxamine caused by Phenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [64]
Phenacemide DMOHS9P Moderate Antagonize the effect of Fluvoxamine when combined with Phenacemide. Epilepsy/seizure [8A61-8A6Z] [31]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Fluvoxamine caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [64]
Paramethadione DMR5ZUP Moderate Antagonize the effect of Fluvoxamine when combined with Paramethadione. Epilepsy/seizure [8A61-8A6Z] [31]
Brivaracetam DMSEPK8 Moderate Antagonize the effect of Fluvoxamine when combined with Brivaracetam. Epilepsy/seizure [8A61-8A6Z] [31]
Clonazepam DMTO13J Moderate Decreased metabolism of Fluvoxamine caused by Clonazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [30]
Lacosamide DMVM6QR Moderate Antagonize the effect of Fluvoxamine when combined with Lacosamide. Epilepsy/seizure [8A61-8A6Z] [31]
Rufinamide DMWE60C Moderate Antagonize the effect of Fluvoxamine when combined with Rufinamide. Epilepsy/seizure [8A61-8A6Z] [31]
Ethotoin DMXWOCP Moderate Decreased metabolism of Fluvoxamine caused by Ethotoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [64]
Vigabatrin DMYT0OG Moderate Antagonize the effect of Fluvoxamine when combined with Vigabatrin. Epilepsy/seizure [8A61-8A6Z] [31]
Carbamazepine DMZOLBI Moderate Decreased metabolism of Fluvoxamine caused by Carbamazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [65]
Eslicarbazepine DMZREFQ Moderate Antagonize the effect of Fluvoxamine when combined with Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [31]
Cannabidiol DM0659E Minor Decreased metabolism of Fluvoxamine caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [28]
Timolol DM3NXRU Moderate Decreased metabolism of Fluvoxamine caused by Timolol mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [66]
Ethacrynic acid DM60QMR Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Ethacrynic acid. Essential hypertension [BA00] [46]
Bendroflumethiazide DM7EVLC Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Bendroflumethiazide. Essential hypertension [BA00] [46]
Nicardipine DMCDYW7 Moderate Decreased metabolism of Fluvoxamine caused by Nicardipine mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [8]
Benzthiazide DMQWZ0H Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Benzthiazide. Essential hypertension [BA00] [46]
Mefenamic acid DMK7HFI Moderate Increased risk of bleeding by the combination of Fluvoxamine and Mefenamic acid. Female pelvic pain [GA34] [26]
Tazemetostat DMWP1BH Moderate Decreased metabolism of Fluvoxamine caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [67]
Solifenacin DMG592Q Moderate Decreased metabolism of Fluvoxamine caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [68]
Mirabegron DMS1GYT Moderate Decreased metabolism of Fluvoxamine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [69]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Fluvoxamine caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [70]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Fluvoxamine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [71]
Itraconazole DMCR1MV Moderate Decreased metabolism of Fluvoxamine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [8]
Terbinafine DMI6HUW Moderate Decreased metabolism of Fluvoxamine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [72]
Miconazole DMPMYE8 Moderate Decreased metabolism of Fluvoxamine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [8]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Fluvoxamine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [8]
Omeprazole DM471KJ Moderate Decreased metabolism of Fluvoxamine caused by Omeprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [38]
Pantoprazole DMSVOCZ Moderate Decreased metabolism of Fluvoxamine caused by Pantoprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [38]
Cisapride DMY7PED Major Decreased metabolism of Fluvoxamine caused by Cisapride mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [73]
Ripretinib DM958QB Moderate Decreased metabolism of Fluvoxamine caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [74]
Avapritinib DMK2GZX Moderate Increased risk of bleeding by the combination of Fluvoxamine and Avapritinib. Gastrointestinal stromal tumour [2B5B] [26]
Acetazolamide DM1AF5U Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Acetazolamide. Glaucoma [9C61] [46]
Methazolamide DM7J2TA Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Methazolamide. Glaucoma [9C61] [46]
Dichlorphenamide DMH7IDQ Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Dichlorphenamide. Glaucoma [9C61] [46]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Fluvoxamine and Sulfinpyrazone. Gout [FA25] [26]
Ergotamine DMKR3C5 Major Additive serotonergic effects by the combination of Fluvoxamine and Ergotamine. Headache [8A80-8A84] [10]
Spironolactone DM2AQ5N Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Spironolactone. Heart failure [BD10-BD1Z] [46]
Triamterene DM2HU9I Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Triamterene. Heart failure [BD10-BD1Z] [46]
Carvedilol DMHTEAO Moderate Decreased metabolism of Fluvoxamine caused by Carvedilol mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [66]
Chlorothiazide DMLHESP Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Chlorothiazide. Heart failure [BD10-BD1Z] [46]
Furosemide DMMQ8ZG Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Furosemide. Heart failure [BD10-BD1Z] [46]
Amiloride DMRTSGP Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Amiloride. Heart failure [BD10-BD1Z] [46]
Bumetanide DMRV7H0 Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Bumetanide. Heart failure [BD10-BD1Z] [46]
Hydroflumethiazide DMVPUQI Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [46]
Torasemide DMXKJ6C Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Torasemide. Heart failure [BD10-BD1Z] [46]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Fluvoxamine and Procarbazine. Hodgkin lymphoma [2B30] [11]
Indinavir DM0T3YH Moderate Decreased metabolism of Fluvoxamine caused by Indinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [8]
MK-1439 DM215WE Minor Decreased metabolism of Fluvoxamine caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [75]
Delavirdine DM3NF5G Moderate Decreased metabolism of Fluvoxamine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [8]
Nevirapine DM6HX9B Moderate Decreased metabolism of Fluvoxamine caused by Nevirapine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [8]
Cobicistat DM6L4H2 Moderate Decreased clearance of Fluvoxamine due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [76]
Dolutegravir DMCZGRE Minor Decreased metabolism of Fluvoxamine caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [77]
Saquinavir DMG814N Moderate Decreased metabolism of Fluvoxamine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [8]
Etravirine DMGV8QU Moderate Decreased metabolism of Fluvoxamine caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [78]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Fluvoxamine caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [74]
Amprenavir DMLMXE0 Minor Decreased metabolism of Fluvoxamine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [79]
Atazanavir DMSYRBX Moderate Decreased metabolism of Fluvoxamine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [80]
Maraviroc DMTL94F Moderate Decreased clearance of Fluvoxamine due to the transporter inhibition by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [81]
Ritonavir DMU764S Moderate Decreased metabolism of Fluvoxamine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [82]
Simvastatin DM30SGU Moderate Decreased metabolism of Fluvoxamine caused by Simvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [48]
Fluvastatin DM4MDJY Moderate Decreased metabolism of Fluvoxamine caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [74]
Lovastatin DM9OZWQ Moderate Decreased metabolism of Fluvoxamine caused by Lovastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [48]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Fluvoxamine caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [83]
Cerivastatin DMXCM7H Moderate Decreased metabolism of Fluvoxamine caused by Cerivastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [48]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Fluvoxamine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [74]
Losartan DM72JXH Moderate Decreased metabolism of Fluvoxamine caused by Losartan mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [8]
Nebivolol DM7F1PA Moderate Decreased metabolism of Fluvoxamine caused by Nebivolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [66]
Nisoldipine DM7ISKJ Moderate Decreased metabolism of Fluvoxamine caused by Nisoldipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [8]
Isradipine DMA5XGH Moderate Decreased metabolism of Fluvoxamine caused by Isradipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [8]
Verapamil DMA7PEW Moderate Decreased metabolism of Fluvoxamine caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [8]
Indapamide DMGN1PW Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Indapamide. Hypertension [BA00-BA04] [46]
Trichlormethiazide DMHAQCO Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Trichlormethiazide. Hypertension [BA00-BA04] [46]
Labetalol DMK8U72 Moderate Decreased metabolism of Fluvoxamine caused by Labetalol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [66]
Metoprolol DMOJ0V6 Moderate Decreased metabolism of Fluvoxamine caused by Metoprolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [66]
Felodipine DMOSW35 Moderate Decreased metabolism of Fluvoxamine caused by Felodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [8]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Hydrochlorothiazide. Hypertension [BA00-BA04] [46]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Fluvoxamine and Dipyridamole. Hypertension [BA00-BA04] [26]
Tolvaptan DMIWFRL Moderate Decreased metabolism of Fluvoxamine caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [84]
Fludrocortisone DMUDIR8 Moderate Decreased metabolism of Fluvoxamine caused by Fludrocortisone mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [8]
Pirfenidone DM6VZFQ Major Decreased metabolism of Fluvoxamine caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [28]
Retapamulin DM9JXB7 Minor Decreased metabolism of Fluvoxamine caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [85]
Givosiran DM5PFIJ Moderate Decreased metabolism of Fluvoxamine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [86]
Lesinurad DMUR64T Moderate Decreased metabolism of Fluvoxamine caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [87]
Meclofenamic acid DM05FXR Moderate Increased risk of bleeding by the combination of Fluvoxamine and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [45]
Rhucin DM3ADGP Moderate Decreased metabolism of Fluvoxamine caused by Rhucin mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [88]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Fluvoxamine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [89]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Fluvoxamine caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [74]
Ramelteon DM7IW9J Major Decreased metabolism of Fluvoxamine caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [90]
Flurazepam DMAL4G0 Moderate Decreased metabolism of Fluvoxamine caused by Flurazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [30]
Triazolam DMETYK5 Moderate Decreased metabolism of Fluvoxamine caused by Triazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [30]
Melatonin DMKWFBT Moderate Decreased metabolism of Fluvoxamine caused by Melatonin mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [74]
Tasimelteon DMLOQ1V Major Decreased metabolism of Fluvoxamine caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [91]
ITI-007 DMUQ1DO Major Decreased metabolism of Fluvoxamine caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [92]
Zolpidem DMWOSKJ Moderate Decreased metabolism of Fluvoxamine caused by Zolpidem mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [74]
Quazepam DMY4D87 Moderate Decreased metabolism of Fluvoxamine caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [30]
Estazolam DMZGXUM Moderate Decreased metabolism of Fluvoxamine caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [30]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Fluvoxamine and Polyethylene glycol. Irritable bowel syndrome [DD91] [93]
Alosetron DML2A03 Major Decreased metabolism of Fluvoxamine caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [34]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Fluvoxamine caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [94]
Ticlopidine DMO946V Moderate Increased risk of bleeding by the combination of Fluvoxamine and Ticlopidine. Ischaemic/haemorrhagic stroke [8B20] [26]
Naloxegol DML0B41 Minor Decreased metabolism of Fluvoxamine caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [95]
Pemigatinib DM819JF Moderate Decreased metabolism of Fluvoxamine caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [28]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Fluvoxamine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [28]
Testosterone DM7HUNW Moderate Decreased metabolism of Fluvoxamine caused by Testosterone mediated inhibition of CYP450 enzyme. Low bone mass disorder [FB83] [8]
Crizotinib DM4F29C Moderate Decreased metabolism of Fluvoxamine caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [96]
Brigatinib DM7W94S Moderate Decreased metabolism of Fluvoxamine caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [74]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Fluvoxamine and Porfimer Sodium. Lung cancer [2C25] [97]
Ceritinib DMB920Z Moderate Decreased metabolism of Fluvoxamine caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [98]
Erlotinib DMCMBHA Moderate Decreased metabolism of Fluvoxamine caused by Erlotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [99]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Fluvoxamine caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [100]
PF-06463922 DMKM7EW Moderate Decreased metabolism of Fluvoxamine caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [101]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Fluvoxamine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [102]
Osimertinib DMRJLAT Moderate Decreased metabolism of Fluvoxamine caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [103]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Fluvoxamine caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [104]
Selpercatinib DMZR15V Moderate Decreased metabolism of Fluvoxamine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [28]
Lumefantrine DM29GAD Moderate Decreased metabolism of Fluvoxamine caused by Lumefantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [74]
Halofantrine DMOMK1V Major Decreased metabolism of Fluvoxamine caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [105]
GDC-0199 DMH0QKA Moderate Decreased metabolism of Fluvoxamine caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [74]
IPI-145 DMWA24P Moderate Decreased metabolism of Fluvoxamine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [106]
Acalabrutinib DM7GCVW Moderate Increased risk of bleeding by the combination of Fluvoxamine and Acalabrutinib. Mature B-cell lymphoma [2A85] [26]
Ibrutinib DMHZCPO Moderate Increased risk of bleeding by the combination of Fluvoxamine and Ibrutinib. Mature B-cell lymphoma [2A85] [26]
Vincristine DMINOX3 Moderate Decreased metabolism of Fluvoxamine caused by Vincristine mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [8]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Fluvoxamine caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [107]
Selumetinib DMC7W6R Moderate Decreased metabolism of Fluvoxamine caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [28]
Estrone DM5T6US Moderate Decreased metabolism of Fluvoxamine caused by Estrone mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [8]
Dienestrol DMBSXI0 Moderate Decreased metabolism of Fluvoxamine caused by Dienestrol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [8]
Conjugated estrogens DMLT0E1 Moderate Decreased metabolism of Fluvoxamine caused by Conjugated estrogens mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [8]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of Fluvoxamine caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [8]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Fluvoxamine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [108]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Fluvoxamine caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [13]
Zolmitriptan DM1IB4Q Moderate Decreased metabolism of Fluvoxamine caused by Zolmitriptan mediated inhibition of CYP450 enzyme. Migraine [8A80] [28]
Dihydroergotamine DM5IKUF Major Additive serotonergic effects by the combination of Fluvoxamine and Dihydroergotamine. Migraine [8A80] [10]
Ubrogepant DM749I3 Moderate Decreased metabolism of Fluvoxamine caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [109]
Propranolol DM79NTF Moderate Decreased metabolism of Fluvoxamine caused by Propranolol mediated inhibition of CYP450 enzyme. Migraine [8A80] [66]
Almogran DM7I64Z Major Additive serotonergic effects by the combination of Fluvoxamine and Almogran. Migraine [8A80] [10]
Frovatriptan DM7RE8P Major Additive serotonergic effects by the combination of Fluvoxamine and Frovatriptan. Migraine [8A80] [10]
Rizatriptan DMDJMA3 Major Additive serotonergic effects by the combination of Fluvoxamine and Rizatriptan. Migraine [8A80] [10]
Naratriptan DMO50U2 Major Additive serotonergic effects by the combination of Fluvoxamine and Naratriptan. Migraine [8A80] [10]
Sumatriptan DMVYXR8 Major Additive serotonergic effects by the combination of Fluvoxamine and Sumatriptan. Migraine [8A80] [10]
Eletriptan DMW649X Major Additive serotonergic effects by the combination of Fluvoxamine and Eletriptan. Migraine [8A80] [10]
Exjade DMHPRWG Moderate Increased risk of bleeding by the combination of Fluvoxamine and Exjade. Mineral absorption/transport disorder [5C64] [26]
Flibanserin DM70DTN Moderate Decreased metabolism of Fluvoxamine caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [110]
Midazolam DMXOELT Moderate Decreased metabolism of Fluvoxamine caused by Midazolam mediated inhibition of CYP450 enzyme. Mood/affect symptom [MB24] [30]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Fluvoxamine and Panobinostat. Multiple myeloma [2A83] [26]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Fluvoxamine and Thalidomide. Multiple myeloma [2A83] [111]
Siponimod DM2R86O Major Decreased metabolism of Fluvoxamine caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [74]
Ozanimod DMT6AM2 Moderate Additive serotonergic effects by the combination of Fluvoxamine and Ozanimod. Multiple sclerosis [8A40] [112]
Rifabutin DM1YBHK Moderate Decreased metabolism of Fluvoxamine caused by Rifabutin mediated inhibition of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [8]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Fluvoxamine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [28]
Nilotinib DM7HXWT Moderate Decreased metabolism of Fluvoxamine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [113]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Fluvoxamine and Ruxolitinib. Myeloproliferative neoplasm [2A20] [26]
Imatinib DM7RJXL Moderate Decreased metabolism of Fluvoxamine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [114]
Dasatinib DMJV2EK Moderate Increased risk of bleeding by the combination of Fluvoxamine and Dasatinib. Myeloproliferative neoplasm [2A20] [26]
Prasugrel DM7MT6E Moderate Increased risk of bleeding by the combination of Fluvoxamine and Prasugrel. Myocardial infarction [BA41-BA43] [26]
Vorapaxar DMA16BR Moderate Increased risk of bleeding by the combination of Fluvoxamine and Vorapaxar. Myocardial infarction [BA41-BA43] [26]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Fluvoxamine and Tirofiban. Myocardial infarction [BA41-BA43] [26]
Modafinil DMYILBE Minor Decreased metabolism of Fluvoxamine caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [74]
Droperidol DM0DXA8 Moderate Decreased metabolism of Fluvoxamine caused by Droperidol mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [115]
Rolapitant DM8XP26 Moderate Decreased metabolism of Fluvoxamine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [116]
Palonosetron DMBHMOX Major Increased risk of prolong QT interval by the combination of Fluvoxamine and Palonosetron. Nausea/vomiting [MD90] [13]
Granisetron DMIUW25 Major Additive serotonergic effects by the combination of Fluvoxamine and Granisetron. Nausea/vomiting [MD90] [13]
Dolasetron DMMG26Z Major Additive serotonergic effects by the combination of Fluvoxamine and Dolasetron. Nausea/vomiting [MD90] [13]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Fluvoxamine and Ondansetron. Nausea/vomiting [MD90] [13]
E-2007 DMJDYNQ Moderate Antagonize the effect of Fluvoxamine when combined with E-2007. Neuropathy [8C0Z] [31]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Fluvoxamine and Bupropion. Nicotine use disorder [6C4A] [13]
Entrectinib DMMPTLH Moderate Decreased metabolism of Fluvoxamine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [117]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Fluvoxamine and Sibutramine. Obesity [5B80-5B81] [118]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Fluvoxamine and Lorcaserin. Obesity [5B80-5B81] [119]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Fluvoxamine and Dexfenfluramine. Obesity [5B80-5B81] [10]
Chlorthalidone DM4DMBT Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Chlorthalidone. Oedema [MG29] [46]
Metolazone DMB39LO Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Metolazone. Oedema [MG29] [46]
Polythiazide DMCH80F Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Polythiazide. Oedema [MG29] [46]
Urea DMUK75B Moderate Increased risk of hyponatremia by the combination of Fluvoxamine and Urea. Oesophagitis [DA24] [46]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Fluvoxamine caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [120]
Caffeine DMKBJWP Moderate Decreased metabolism of Fluvoxamine caused by Caffeine mediated inhibition of CYP450 enzyme. Orthostatic hypotension [BA21] [34]
Valdecoxib DMAY7H4 Moderate Decreased metabolism of Fluvoxamine caused by Valdecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [121]
Diclofenac DMPIHLS Moderate Increased risk of bleeding by the combination of Fluvoxamine and Diclofenac. Osteoarthritis [FA00-FA05] [26]
Naproxen DMZ5RGV Moderate Increased risk of bleeding by the combination of Fluvoxamine and Naproxen. Osteoarthritis [FA00-FA05] [26]
Olaparib DM8QB1D Moderate Decreased metabolism of Fluvoxamine caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [122]
Pentazocine DM1XBHS Major Additive serotonergic effects by the combination of Fluvoxamine and Pentazocine. Pain [MG30-MG3Z] [10]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Fluvoxamine and Dextropropoxyphene. Pain [MG30-MG3Z] [123]
Butorphanol DM5KYPJ Moderate Additive CNS depression effects by the combination of Fluvoxamine and Butorphanol. Pain [MG30-MG3Z] [52]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Fluvoxamine and Oxymorphone. Pain [MG30-MG3Z] [52]
Aspirin DM672AH Moderate Increased risk of bleeding by the combination of Fluvoxamine and Aspirin. Pain [MG30-MG3Z] [45]
Etodolac DM6WJO9 Moderate Increased risk of bleeding by the combination of Fluvoxamine and Etodolac. Pain [MG30-MG3Z] [26]
Diflunisal DM7EN8I Moderate Increased risk of bleeding by the combination of Fluvoxamine and Diflunisal. Pain [MG30-MG3Z] [26]
Ibuprofen DM8VCBE Moderate Increased risk of bleeding by the combination of Fluvoxamine and Ibuprofen. Pain [MG30-MG3Z] [26]
Nabumetone DMAT2XH Moderate Increased risk of bleeding by the combination of Fluvoxamine and Nabumetone. Pain [MG30-MG3Z] [26]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Fluvoxamine and Levorphanol. Pain [MG30-MG3Z] [52]
Hydromorphone DMHP21E Moderate Additive CNS depression effects by the combination of Fluvoxamine and Hydromorphone. Pain [MG30-MG3Z] [52]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Fluvoxamine and Dezocine. Pain [MG30-MG3Z] [52]
Codeine DMJX6ZG Moderate Additive CNS depression effects by the combination of Fluvoxamine and Codeine. Pain [MG30-MG3Z] [52]
Nalbuphine DMOSQGU Moderate Additive CNS depression effects by the combination of Fluvoxamine and Nalbuphine. Pain [MG30-MG3Z] [52]
Buprenorphine DMPRI8G Moderate Additive CNS depression effects by the combination of Fluvoxamine and Buprenorphine. Pain [MG30-MG3Z] [52]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Fluvoxamine and Hydrocodone. Pain [MG30-MG3Z] [52]
Tramadol DMRQD04 Major Increased risk of lowers seizure threshold by the combination of Fluvoxamine and Tramadol. Pain [MG30-MG3Z] [124]
Piroxicam DMTK234 Moderate Increased risk of bleeding by the combination of Fluvoxamine and Piroxicam. Pain [MG30-MG3Z] [26]
Meperidine DMX4GND Major Additive serotonergic effects by the combination of Fluvoxamine and Meperidine. Pain [MG30-MG3Z] [10]
Oxycodone DMXLKHV Moderate Additive CNS depression effects by the combination of Fluvoxamine and Oxycodone. Pain [MG30-MG3Z] [52]
Trimethadione DM0Q8MZ Moderate Antagonize the effect of Fluvoxamine when combined with Trimethadione. Pancreatic cancer [2C10] [31]
Albendazole DMYZ57N Moderate Decreased metabolism of Fluvoxamine caused by Albendazole mediated inhibition of CYP450 enzyme. Parasitic worm infestation [1F90] [8]
Safinamide DM0YWJC Moderate Additive serotonergic effects by the combination of Fluvoxamine and Safinamide. Parkinsonism [8A00] [112]
Istradefylline DM20VSK Moderate Decreased metabolism of Fluvoxamine caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [125]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Fluvoxamine and Rasagiline. Parkinsonism [8A00] [11]
Ropinirole DMA6S1D Moderate Decreased metabolism of Fluvoxamine caused by Ropinirole mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [126]
Pimavanserin DMR7IVC Moderate Decreased metabolism of Fluvoxamine caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [127]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Fluvoxamine caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [8]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Fluvoxamine and Lindane. Pediculosis [1G00] [128]
Esomeprazole DM7BN0X Moderate Decreased metabolism of Fluvoxamine caused by Esomeprazole mediated inhibition of CYP450 enzyme. Peptic ulcer [DA61] [38]
Dapsone DM4LT8A Moderate Decreased metabolism of Fluvoxamine caused by Dapsone mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [8]
Lefamulin DME6G97 Moderate Decreased metabolism of Fluvoxamine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [129]
Prednisone DM2HG4X Moderate Decreased metabolism of Fluvoxamine caused by Prednisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [8]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Fluvoxamine and Choline salicylate. Postoperative inflammation [1A00-CA43] [26]
Betamethasone DMAHJEF Moderate Decreased metabolism of Fluvoxamine caused by Betamethasone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [8]
Hydrocortisone DMGEMB7 Moderate Decreased metabolism of Fluvoxamine caused by Hydrocortisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [8]
Ketorolac DMI4EL5 Moderate Increased risk of bleeding by the combination of Fluvoxamine and Ketorolac. Postoperative inflammation [1A00-CA43] [26]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Fluvoxamine and Bromfenac. Postoperative inflammation [1A00-CA43] [26]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Fluvoxamine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [130]
Progesterone DMUY35B Moderate Decreased metabolism of Fluvoxamine caused by Progesterone mediated inhibition of CYP450 enzyme. Preterm labour/delivery [JB00] [8]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Fluvoxamine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [131]
Enzalutamide DMGL19D Moderate Decreased metabolism of Fluvoxamine caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [132]
Darolutamide DMV7YFT Minor Decreased metabolism of Fluvoxamine caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [133]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Fluvoxamine caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [134]
Silodosin DMJSBT6 Moderate Decreased metabolism of Fluvoxamine caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [135]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Fluvoxamine caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [136]
Finasteride DMWV3TZ Moderate Decreased metabolism of Fluvoxamine caused by Finasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [8]
Ambrisentan DMD1QXW Minor Decreased metabolism of Fluvoxamine caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [137]
Bosentan DMIOGBU Moderate Decreased metabolism of Fluvoxamine caused by Bosentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [138]
Treprostinil DMTIQF3 Moderate Increased risk of bleeding by the combination of Fluvoxamine and Treprostinil. Pulmonary hypertension [BB01] [26]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Fluvoxamine and Iloprost. Pulmonary hypertension [BB01] [26]
Everolimus DM8X2EH Moderate Decreased clearance of Fluvoxamine due to the transporter inhibition by Everolimus. Renal cell carcinoma [2C90] [139]
Axitinib DMGVH6N Moderate Decreased metabolism of Fluvoxamine caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [28]
Temsirolimus DMS104F Moderate Decreased metabolism of Fluvoxamine caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [140]
Meloxicam DM2AR7L Moderate Increased risk of bleeding by the combination of Fluvoxamine and Meloxicam. Rheumatoid arthritis [FA20] [26]
Sulindac DM2QHZU Moderate Increased risk of bleeding by the combination of Fluvoxamine and Sulindac. Rheumatoid arthritis [FA20] [26]
Upadacitinib DM32B5U Moderate Decreased metabolism of Fluvoxamine caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [141]
Celecoxib DM6LOQU Moderate Decreased metabolism of Fluvoxamine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [142]
Oxaprozin DM9UB0P Moderate Increased risk of bleeding by the combination of Fluvoxamine and Oxaprozin. Rheumatoid arthritis [FA20] [26]
Tofacitinib DMBS370 Moderate Decreased metabolism of Fluvoxamine caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [74]
Flurbiprofen DMGN4BY Moderate Increased risk of bleeding by the combination of Fluvoxamine and Flurbiprofen. Rheumatoid arthritis [FA20] [26]
Fenoprofen DML5VQ0 Moderate Increased risk of bleeding by the combination of Fluvoxamine and Fenoprofen. Rheumatoid arthritis [FA20] [26]
Dexamethasone DMMWZET Moderate Decreased metabolism of Fluvoxamine caused by Dexamethasone mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [8]
Indomethacin DMSC4A7 Moderate Increased risk of bleeding by the combination of Fluvoxamine and Indomethacin. Rheumatoid arthritis [FA20] [26]
Tolmetin DMWUIJE Moderate Increased risk of bleeding by the combination of Fluvoxamine and Tolmetin. Rheumatoid arthritis [FA20] [26]
Quetiapine DM1N62C Moderate Decreased metabolism of Fluvoxamine caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [143]
Thioridazine DM35M8J Major Decreased metabolism of Fluvoxamine caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [144]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Fluvoxamine caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [145]
Haloperidol DM96SE0 Moderate Decreased metabolism of Fluvoxamine caused by Haloperidol mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [146]
Chlorpromazine DMBGZI3 Moderate Decreased metabolism of Fluvoxamine caused by Chlorpromazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [74]
Clozapine DMFC71L Moderate Decreased metabolism of Fluvoxamine caused by Clozapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [34]
Ziprasidone DMM58JY Minor Decreased metabolism of Fluvoxamine caused by Ziprasidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [147]
Olanzapine DMPFN6Y Moderate Decreased metabolism of Fluvoxamine caused by Olanzapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [148]
Asenapine DMSQZE2 Moderate Decreased metabolism of Fluvoxamine caused by Asenapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [149]
Pimozide DMW83TP Major Decreased metabolism of Fluvoxamine caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [74]
Salicyclic acid DM2F8XZ Moderate Increased risk of bleeding by the combination of Fluvoxamine and Salicyclic acid. Seborrhoeic dermatitis [EA81] [45]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Fluvoxamine and Fentanyl. Sensation disturbance [MB40] [10]
Sufentanil DMU7YEL Major Additive serotonergic effects by the combination of Fluvoxamine and Sufentanil. Sensation disturbance [MB40] [10]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Fluvoxamine caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [150]
Vardenafil DMTBGW8 Moderate Decreased metabolism of Fluvoxamine caused by Vardenafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [151]
Cevimeline DMWSMND Moderate Decreased metabolism of Fluvoxamine caused by Cevimeline mediated inhibition of CYP450 enzyme. Sjogren syndrome [4A43] [152]
LDE225 DMM9F25 Moderate Decreased metabolism of Fluvoxamine caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [153]
Gefitinib DM15F0X Moderate Decreased metabolism of Fluvoxamine caused by Gefitinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [154]
Larotrectinib DM26CQR Moderate Decreased clearance of Fluvoxamine due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [74]
Methylprednisolone DM4BDON Moderate Decreased metabolism of Fluvoxamine caused by Methylprednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
Cyclophosphamide DM4O2Z7 Moderate Decreased metabolism of Fluvoxamine caused by Cyclophosphamide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
Vinblastine DM5TVS3 Moderate Decreased metabolism of Fluvoxamine caused by Vinblastine mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
Ifosfamide DMCT3I8 Moderate Decreased metabolism of Fluvoxamine caused by Ifosfamide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
Docetaxel DMDI269 Moderate Decreased metabolism of Fluvoxamine caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [155]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Fluvoxamine caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [28]
Armodafinil DMGB035 Minor Decreased metabolism of Fluvoxamine caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [74]
LEE011 DMMX75K Moderate Decreased metabolism of Fluvoxamine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [74]
Etoposide DMNH3PG Moderate Decreased metabolism of Fluvoxamine caused by Etoposide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
Prednisolone DMQ8FR2 Moderate Decreased metabolism of Fluvoxamine caused by Prednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
Norethindrone DMTY169 Moderate Decreased metabolism of Fluvoxamine caused by Norethindrone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
Taxol DMUOT9V Moderate Decreased metabolism of Fluvoxamine caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [156]
Doxorubicin DMVP5YE Moderate Decreased metabolism of Fluvoxamine caused by Doxorubicin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
Vinorelbine DMVXFYE Moderate Decreased metabolism of Fluvoxamine caused by Vinorelbine mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
Pitolisant DM8RFNJ Moderate Decreased metabolism of Fluvoxamine caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [28]
Topiramate DM82Z30 Moderate Antagonize the effect of Fluvoxamine when combined with Topiramate. Substance abuse [6C40] [31]
Warfarin DMJYCVW Moderate Decreased metabolism of Fluvoxamine caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [53]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Fluvoxamine caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [74]
Plicamycin DM7C8YV Moderate Increased risk of bleeding by the combination of Fluvoxamine and Plicamycin. Testicular cancer [2C80] [26]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Fluvoxamine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [157]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Fluvoxamine and Caplacizumab. Thrombocytopenia [3B64] [26]
Anagrelide DMSQ8MD Moderate Decreased metabolism of Fluvoxamine caused by Anagrelide mediated inhibition of CYP450 enzyme. Thrombocytosis [3B63] [158]
Apixaban DM89JLN Moderate Increased risk of bleeding by the combination of Fluvoxamine and Apixaban. Thrombosis [DB61-GB90] [26]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Fluvoxamine and Cangrelor. Thrombosis [DB61-GB90] [26]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Fluvoxamine and Brilinta. Thrombosis [DB61-GB90] [26]
Argatroban DMFI46A Moderate Increased risk of bleeding by the combination of Fluvoxamine and Argatroban. Thrombosis [DB61-GB90] [26]
Dicumarol DMFQCB1 Moderate Decreased metabolism of Fluvoxamine caused by Dicumarol mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [53]
Clopidogrel DMOL54H Major Decreased metabolism of Fluvoxamine caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [159]
Cabozantinib DMIYDT4 Moderate Increased risk of bleeding by the combination of Fluvoxamine and Cabozantinib. Thyroid cancer [2D10] [26]
Tizanidine DMR2IQ4 Major Decreased metabolism of Fluvoxamine caused by Tizanidine mediated inhibition of CYP450 enzyme. Tonus and reflex abnormality [MB47] [34]
Sirolimus DMGW1ID Moderate Decreased metabolism of Fluvoxamine caused by Sirolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [74]
Tacrolimus DMZ7XNQ Moderate Decreased metabolism of Fluvoxamine caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [74]
Tolbutamide DM02AWV Moderate Decreased metabolism of Fluvoxamine caused by Tolbutamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [160]
Saxagliptin DMGXENV Moderate Decreased metabolism of Fluvoxamine caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [28]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Fluvoxamine and Chlorpropamide. Type 2 diabetes mellitus [5A11] [18]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Fluvoxamine and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [18]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Fluvoxamine and Insulin degludec. Type-1/2 diabete [5A10-5A11] [18]
Astemizole DM2HN6Q Major Decreased metabolism of Fluvoxamine caused by Astemizole mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [22]
Triamcinolone DM98IXF Moderate Decreased metabolism of Fluvoxamine caused by Triamcinolone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [8]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Fluvoxamine and Cetirizine. Vasomotor/allergic rhinitis [CA08] [161]
Betrixaban DM2C4RF Moderate Increased risk of bleeding by the combination of Fluvoxamine and Betrixaban. Venous thromboembolism [BD72] [26]
Disopyramide DM5SYZP Moderate Decreased metabolism of Fluvoxamine caused by Disopyramide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [8]
Mexiletine DMCTE9R Moderate Decreased metabolism of Fluvoxamine caused by Mexiletine mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [162]
Propafenone DMPIBJK Moderate Decreased metabolism of Fluvoxamine caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [124]
Flecainide DMSQDLE Moderate Decreased metabolism of Fluvoxamine caused by Flecainide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [124]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Fluvoxamine caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [8]
⏷ Show the Full List of 424 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
⏷ Show the Full List of 24 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Fluvoxamine 100 mg tablet 100 mg Oral Tablet Oral
Fluvoxamine 25 mg tablet 25 mg Oral Tablet Oral
Fluvoxamine 50 mg tablet 50 mg Oral Tablet Oral
Fluvoxamine 100 mg capsule 100 mg 24 HR Extended Release Oral Capsule Oral
Fluvoxamine 150 mg capsule 150 mg 24 HR Extended Release Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7189).
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 075893.
3 ClinicalTrials.gov (NCT04342663) A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection. U.S. National Institutes of Health.
4 Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J. 2009 Jun 30;50(3):441-4.
5 Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
6 Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127-34.
7 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
8 Damkier P, Hansen LL, Brosen K "Effect of fluvoxamine on the pharmacokinetics of quinidine." Eur J Clin Pharmacol 55 (1999): 451-6. [PMID: 10492058]
9 Bertschy G, Vandel S, Vandel B, Allers G, Volmat R "Fluvoxamine-tricyclic antidepressant interaction. An accidental finding." Eur J Clin Pharmacol 40 (1991): 119-20. [PMID: 1905641]
10 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
11 Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20. [PMID: 8227489]
12 Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2. [PMID: 7476638]
13 Canadian Pharmacists Association.
14 Anttila AK, Rasanen I, Leinonen EV "Fluvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold." Ann Pharmacother 35 (2001): 1221-3. [PMID: 11675851]
15 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
16 Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT "Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride." Clin Pharmacol Ther 69 (2001): 194-200. [PMID: 11309547]
17 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
18 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
19 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
20 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
21 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
22 Product Information. Luvox (fluvoxamine). Solvay Pharmaceuticals Inc, Marietta, GA.
23 Becquemont L, Ragueneau I, LeBot MA, Riche C, FunckBrentano C, Jaillon P "Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans." Clin Pharmacol Ther 61 (1997): 619-27. [PMID: 9209244]
24 Product Information. Reminyl (galantamine) Janssen Pharmaceuticals, Titusville, NJ.
25 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
26 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
27 Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
28 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
29 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
30 Fleishaker JC, Hulst LK "A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine." Eur J Clin Pharmacol 46 (1994): 35-9. [PMID: 8005185]
31 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
32 Product Information. Onfi (clobazam). Lundbeck Inc, Deerfield, IL.
33 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
34 Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S "Fluvoxamine is a potent inhibitor of cytochrome P4501A2." Biochem Pharmacol 45 (1993): 1211-4. [PMID: 8466541]
35 Product Information. Elidel (pimecrolimus topical). Novartis Pharmaceuticals, East Hanover, NJ.
36 Gammon GD, Brown TE "Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder." J Child Adolesc Psychopharmacol 3 (1993): 1-10. [PMID: 19630593]
37 Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
38 Christensen M, Tybring G, Mihara K, et al. "Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)." Clin Pharmacol Ther 71 (2002): 141-52. [PMID: 11907488]
39 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
40 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
41 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
42 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
43 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
44 Product Information. Fareston (toremifene). Schering Laboratories, Kenilworth, NJ.
45 Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
46 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
47 Product Information. Tikosyn (dofetilide) Pfizer US Pharmaceuticals, Atlanta, GA.
48 Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
49 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
50 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
51 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
52 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
53 Limke KK, Shelton AR, Elliott ES "Fluvoxamine interaction with warfarin." Ann Pharmacother 36 (2002): 1890-2. [PMID: 12452751]
54 Ekstrom G, Gunnarsson UB "Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes." Drug Metab Dispos 24 (1996): 955-61. [PMID: 8886604]
55 Bertschy G, Baumann P, Eap CB, Baettig D "Probable metabolic interaction between methadone and fluvoxamine in addict patients." Ther Drug Monit 16 (1994): 42-5. [PMID: 8160253]
56 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
57 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
58 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
59 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
60 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
61 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide).".
62 Magnusson M, Bergstrand IC, Bjorkman S, Heijl A, Roth B, Hoglund P "A placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans." Br J Clin Pharmacol 61 (2006): 138-47. [PMID: 16433868]
63 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
64 Mamiya K, Kojima K, Yukawa E, Higuchi S, Ieiri I, Ninomiya H, Tashiro N "Phenytoin intoxication induced by fluvoxamine." Ther Drug Monit 23 (2001): 75-7. [PMID: 11206048]
65 Fritze J, Unsorg B, Lanczik M "Interaction between carbamazepine and fluvoxamine." Acta Psychiatr Scand 84 (1991): 583-4. [PMID: 1792934]
66 Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
67 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
68 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
69 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
70 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
71 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
72 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
73 Bran S, Murray WA, Hirsch IB, Palmer JP "Long QT syndrome during high-dose cisapride." Arch Intern Med 155 (1995): 765-8. [PMID: 7695465]
74 Cerner Multum, Inc. "Australian Product Information.".
75 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
76 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
77 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
78 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
79 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
80 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
81 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
82 Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
83 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
84 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
85 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
86 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
87 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
88 Hyland R, Roe GH, Jones BC, Smith DA "Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil." Br J Clin Pharmaacol 51 (2001): 239-48. [PMID: 11298070]
89 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
90 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
91 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
92 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
93 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
94 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
95 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
96 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
97 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
98 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
99 Product Information. Tarceva (erlotinib). Genentech, South San Francisco, CA.
100 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
101 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
102 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
103 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
104 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
105 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
106 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
107 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
108 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
109 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
110 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
111 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
112 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
113 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
114 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
115 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
116 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
117 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
118 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
119 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
120 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
121 Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
122 Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
123 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
124 Alfaro CL, Lam YWF, Simpson J, Ereshefsky L "CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline." J Clin Psychopharmacol 19 (1999): 155-63. [PMID: 10211917]
125 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
126 Product Information. Noroxin (norfloxacin). Merck & Co, Inc, West Point, PA.
127 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
128 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
129 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
130 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
131 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
132 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
133 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
134 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
135 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
136 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
137 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
138 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
139 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
140 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
141 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
142 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
143 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
144 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
145 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
146 Daniel DG, Randolph C, Jaskiw G, et al "Coadministration of fluvoxamine increases serum concentrations of haloperidol." J Clin Psychopharmacol 14 (1994): 340-3. [PMID: 7806690]
147 Miceli JJ, Smith M, Robarge L, Morse T, Laurent A "The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers." Br J Clin Pharmacol 49(suppl 1) (2000): s71-6. [PMID: 10771458]
148 Albers LJ, Ozdemir V, Marder SR, et al. "Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy." J Clin Psychopharmacol 25 (2005): 170-174. [PMID: 15738749]
149 Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
150 Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
151 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
152 Product Information. Evoxac (cevimeline) Daiichi Pharmaceuticals, Fort lee, NJ.
153 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
154 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
155 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
156 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
157 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
158 Product Information. Agrylin (anagrelide). Roberts Pharmaceutical Corporation, Eatontown, NJ.
159 Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
160 Madsen H, Enggaard TP, Hansen LL, Klitgaard NA, Brosen K "Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide." Clin Pharmacol Ther 69 (2001): 41-7. [PMID: 11180037]
161 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.
162 Kusumoto M, Ueno K, Oda A, Takeda K, Mashimo K, Takaya K, Fujimura Y, Nishihori T, Tanaka K "Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men." Clin Pharmacol Ther 69 (2001): 104-7. [PMID: 11240973]